Guidelines for the successful treatment of XXXX with @entity1012 .

@entity1 @entity3609 @entity1012 @entity66 @entity75 @entity600 @entity2696 @entity911
BACKGROUND/PURPOSE: @entity3609 or @entity2696 ( @entity2696 ) is a disfiguring benign lesion commonly seen in the neck and face regions in @entity1 . Extensive neck/face resectional surgery is frequently performed for this condition, often with disappointing results. An attractive alternative to surgery is injection, sclerosing therapy. @entity1012 injection therapy has been characterised as a novel treatment of @entity2696 since 1987. Since this first report, there have been a number of articles from different institutions reporting variable success rates with its use. This has resulted in uncertainty and @entity911 among physicians, surgeons and parents alike as to in whom, when, and how to treat @entity1 with this modality. METHOD: A prospective study over a five-year period. Thirty-five @entity1 were injected with this agent, 1 to 4 times, depending on response. RESULT: In @entity1 with macrocystic @entity2696 , complete regression was achieved in 96 %. @entity1 with microcystic @entity2696 responded poorly or not at all. CONCLUSION: The anatomical appearance of the @entity600 on computerised tomography (or sonar) scan is crucial in determining the treatment strategy taken; @entity75 respond almost universally to @entity1012 injections, whereas @entity1 with @entity66 generally do not respond and should therefore not be injected with this agent.
